Virtual Program

Our 2-day virtual summit, to be held 20-21 September, features thought-provoking plenary sessions, topical presentations and discussions, educational symposia and speakers from a diverse array of backgrounds excited to share with you a wealth of ideas, experiences, and perspectives on the latest HEOR topics in Asia Pacific. 

Special Bonus: Registration includes extended access to all session playback recordings through 21 October 2022.

Note: Times shown within the program are in Korean Standard Time (KST). The Summit will be presented in English without translation.

ICER Thresholds Across Asia - What They Are, How Are They Determined and Used? What Are the Implications of This for Patient Access?

Speaker(s)

Moderator: Colman Taylor, PhD, Health Technology Analysts, Surry Hills, NSW, Australia
Panelists: Jonathan Karnon, PhD, Flinders University, Adelaide, SA, Australia; Bor-Sheng Ko, MD, PhD, BMT Unit and Hematology Division, Department of Internal Medicine, Department of Hematological Oncology, National Taiwan University Cancer Center, New Taipei City, TPE, Taiwan; Jing Wu, PhD, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, 12, China

Presentation Documents

ISSUE: ICER thresholds are used as a cut-off point by many HTA’s to assess value for money and whether or not a new medicine should be reimbursed. Whilst there are strengths and limitations using thresholds, there remains outstanding knowledge gaps in how ICER thresholds should be estimated and applied now and into the future

OVERVIEW: ICER thresholds in the Asia Pacific region vary in terms of: whether they are used, the threshold dollar value, and how these thresholds are estimated, including based on GDP, willingness to pay or unclear methods.

There are advantages and disadvantages of using ICER thresholds for decision-making. Several disadvantages are possible to overcome by allowing flexibility/modification in the threshold over time or for different disease, patient, or other factors.

The derivation of an ICER value is also impacted by the evaluation framework and approaches required by the HTA agency and the data used to conduct the CEA. Which elements of value can be incorporated, what perspective is taken, what time horizon and discounting are accepted in the CEA, and how certain are the results. These factors should also be considered when estimating and applying ICER thresholds to reimbursement decisions.

It is expected that ICER thresholds will continue to be used but there are opportunities to evolve their determination and application to achieve the best balance between efficiency and patient access.

Differences in the determination and application of ICER thresholds across the Asia Pacific region will be discussed. Panelists will be encouraged to offer their thoughts on what can be done to improve this for positive impact on decision-making and patient access to innovative technologies.

Each speaker will present for approximately 10-15 minutes, with around 20 minutes for debate and questions. Speakers from different geographies have been chosen to represent variety of HTA approaches and maturity.

Code

IP12